Friday, 16 October 2026European Markets

ADC SIIC Stock Tumbles 23% As Market Underperforms

Loading stream...

(vianews) - investors responded negatively to adc siic (aldv.pa) performance on wednesday, sending its stock plummeting 23.98% to eur0.07 by 16:08 est despite cac 40's rise of 0.48% compared to eur8,144.43 during this session. while adc siic recently experienced an upward trend, its 52-week high of eur0.08 remains 14% above current trading levels.

about adc siic

alliance developpement capital siic (adc siic) is a publicly traded real estate investment company focused on owning and managing residential properties near paris, france. formerly known as ad capital sa, adc siic's head office can be found in saint-josse-ten-noode, belgium.

yearly analysis

technical analysis

equity analysis

negative roe ratios indicate that a company is failing to generate profits efficiently and use shareholder equity effectively, thus depriving shareholders of its returns and not effectively managing their resources. an investment decision maker might take this into consideration when making their decisions as it indicates potential financial difficulties or mismanagement of resources by management practices that need further investigation; they might compare current roes against historical averages or those of similar companies within the same industry for comparison purposes.

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com